Article
Medicine, General & Internal
Edoardo Francini, Francesco Montagnani, Pier Vitale Nuzzo, Miguel Gonzalez-Velez, Nimira S. Alimohamed, Pietro Rosellini, Irene Moreno-Candilejo, Antonio Cigliola, Jaime Rubio-Perez, Francesca Crivelli, Grace K. Shaw, Li Zhang, Roberto Petrioli, Carmelo Bengala, Guido Francini, Jesus Garcia-Foncillas, Christopher J. Sweeney, Celestia S. Higano, Alan H. Bryce, Lauren C. Harshman, Richard Lee-Ying, Daniel Y. C. Heng
Summary: The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases was associated with longer overall survival, especially in patients with high-volume disease.
Review
Oncology
Evangelos Terpos, Elena Zamagni, Suzanne Lentzsch, Matthew T. Drake, Ramon Garcia-Sanz, Niels Abildgaard, Ioannis Ntanasis-Stathopoulos, Fredrik Schjesvold, Javier de la Rubia, Charalampia Kyriakou, Jens Hillengass, Sonja Zweegman, Michele Cavo, Philippe Moreau, Jesus San-Miguel, Meletios A. Dimopoulos, Nikhil Munshi, Brian G. M. Durie, Noopur Raje
Summary: The Bone Working Group of the International Myeloma Working Group recommends the use of zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma. Denosumab can be considered for patients with renal impairment. Cement augmentation is effective for painful vertebral compression fractures.
Article
Orthopedics
Felasfa Wodajo, Matthew Colman, Patrick Getty
Summary: The Musculoskeletal Tumor Society, in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology, has developed a clinical practice guideline for the care of patients with metastatic carcinoma and myeloma of the femur. The guideline, developed by an Expert Panel using a standardized process, includes thirteen recommendations covering various aspects such as imaging, bone-modifying agents, radiation therapy, and surgical reconstruction. The panel recommends the use of bone-modifying agents to reduce femur fractures, regardless of tumor histology, and the use of radiation therapy for patients at increased risk. Arthroplasty is also suggested for patients with pathologic fractures in the femur to improve function and reduce the need for postoperative radiation therapy.
JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
(2023)
Article
Oncology
Aaron P. Mitchell, Akriti Mishra, Katherine S. Panageas, Allison Lipitz-Snyderman, Peter B. Bach, Michael J. Morris
Summary: This study found that more than one-quarter of patients with mCSPC who had no evidence of high osteoporotic fracture risk received BMAs in recent years, suggesting potential overuse.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Huiping Li, Yan Huang, Zhendong Chen, Aiping Zeng, Helong Zhang, Yan Yu, Shihong Wei, Qingshan Li, Xiaojia Wang, Xiangcai Wang, Xiuwen Wang, Runxiang Yang, Xiumei Dai, Minghong Bi, Tao Sun, Qingyuan Zhang, Cuicui Han, Yujie Li, Xiaoyan Kang, Yaxin Liu, Li Zhang
Summary: This phase III trial aimed to compare the efficacy, safety, and pharmacokinetics between QL1206 and denosumab in patients with bone metastases from solid tumors. The study found that QL1206 had promising efficacy, tolerable safety, and pharmacokinetics equivalent to denosumab, which could benefit patients with bone metastases from solid tumors.
Article
Pharmacology & Pharmacy
Andrew H. Tam, Allison J. Schepers, Angel Qin, Victoria R. Nachar
Summary: This study is the first to examine the extended-interval dosing of zoledronic acid in metastatic lung cancer patients. The incidence and time to skeletal-related events at 1 year were similar between the Q12wk and Q4wk dosing groups, but the Q12wk dosing group had a longer overall survival time.
ANNALS OF PHARMACOTHERAPY
(2021)
Article
Oncology
Christina Billias, Megan Langer, Sorana Ursu, Rebecca Schorr
Summary: This study found that multiple myeloma patients receiving chemotherapy without a bone-modifying agent had higher rates of skeletal-related events compared to those receiving chemotherapy with a bone-modifying agent. This highlights the benefit of utilizing bone-modifying agents for preventing skeletal-related events in all multiple myeloma patients undergoing chemotherapy.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Article
Oncology
Chin-Yao Shen, Philip Chun-Ming Au, Yeon-Hee Baek, Ching-Lung Cheung, Wei-Pang Chung, Ju Hwan Kim, Nora J. Kleinman, Tai-Chung Lam, Tzu-Chi Liao, Tzu-Chieh Lin, Ju-Young Shin, Chor-Wing Sing, Ian Chi Kei Wong, Edward Chia-Cheng Lai
Summary: This study evaluated and compared the treatment persistence and re-initiation with different bone-targeting agents among Asian patients with bone metastases. The results showed that Denosumab had a lower risk of interruption compared to other bisphosphonates in Taiwan and Hong Kong, while Pamidronate had a higher risk of interruption compared to Zoledronic acid in Taiwan and Korea.
Article
Oncology
Cristina Encinas, Jose-Angel Hernandez-Rivas, Albert Oriol, Laura Rosinol, Maria-Jesus Blanchard, Jose-Maria Bellon, Ramon Garcia-Sanz, Javier de la Rubia, Ana Lopez de la Guia, Ana Jimenez-Ubieto, Isidro Jarque, Belen Inigo, Victoria Dourdil, Felipe de Arriba, Clara Cuellar Perez-Avila, Yolanda Gonzalez, Miguel-Teodoro Hernandez, Joan Bargay, Miguel Granell, Paula Rodriguez-Otero, Maialen Silvent, Carmen Cabrera, Rafael Rios, Adrian Alegre, Mercedes Gironella, Marta-Sonia Gonzalez, Anna Sureda, Antonia Sampol, Enrique M. Ocio, Isabel Krsnik, Antonio Garcia, Aranzazu Garcia-Mateo, Joan-Alfons Soler, Jesus Martin, Jose-Maria Arguinano, Maria-Victoria Mateos, Joan Blade, Jesus F. San-Miguel, Juan-Jose Lahuerta, Joaquin Martinez-Lopez
Summary: Infections are common and serious complications in patients with multiple myeloma. A risk score based on certain variables can help predict the probability of early severe infection, allowing for better identification of patients who would benefit from preventive measures.
BLOOD CANCER JOURNAL
(2022)
Article
Hematology
Jessica S. Little, Megha Tandon, Joseph Seungpyo Hong, Omar Nadeem, Adam S. Sperling, Noopur Raje, Nikhil Munshi, Matthew Frigault, Sara Barmettler, Sarah P. Hammond
Summary: Infections are a significant complication following BCMA-directed CAR T-cell therapy, with respiratory infections being the most common, particularly after day 100. Hypogammaglobulinemia and early respiratory infection diagnosis are independent risk factors for late respiratory infections.
Article
Oncology
Aaron P. Mitchell, Akriti Mishra Meza, Katherine S. Panageas, Allison Lipitz-Snyderman, Azeez Farooki, Michael J. Morris
Summary: The study found that two-thirds of mCRPC patients with bone metastases received bone modifying agents (BMAs) within 180 days after initiating CDT. A greater proportion of patients without bone metastasis may warrant BMA therapy for osteoporotic fracture prevention. Some patients with bone metastasis may be able to delay BMA initiation until CRPC.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Review
Pharmacology & Pharmacy
T. John Martin, Rachelle W. Johnson
Summary: The sequence similarity between the amino-terminal regions of parathyroid hormone (PTH) and PTH-related protein (PTHrP) allows them to share actions at a common site, the PTH1 receptor. PTHrP plays various roles in breast cancer, including promoting bone metastasis and inhibiting tumor progression. Some of the actions of PTHrP are not mediated through the PTH1 receptor, indicating non-canonical actions.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Health Care Sciences & Services
Jiaqi Gao, Huiping Liang, Yun Qian, Junhai Pan, Wei Liu, Weilin Qi, Wei Zhou, Xiaolong Ge, Xianfa Wang
Summary: This study demonstrated that the preoperative CCR can effectively predict postoperative complications in gastric cancer patients, with important clinical implications.
ANNALS OF PALLIATIVE MEDICINE
(2021)
Article
Anesthesiology
Luciano Frassanito, Pietro Paolo Giuri, Francesco Vassalli, Alessandra Piersanti, Manuel Ignacio Monge Garcia, Chiara Sonnino, Bruno Antonio Zanfini, Stefano Catarci, Massimo Antonelli, Gaetano Draisci
Summary: This study investigated the combination of Hypotension Prediction Index (HPI) and a pre-defined Goal Directed Therapy (GDT) hemodynamic protocol to reduce intraoperative hypotension (IOH) in patients undergoing major gynaecologic oncologic surgery. The results showed that using a machine learning-derived algorithm to predict hypotension, in addition to GDT based on stroke volume index optimization, significantly reduced the occurrence of IOH.
JOURNAL OF CLINICAL MONITORING AND COMPUTING
(2023)
Article
Oncology
Fernando Carlos-Rivera, Jorge A. Guzman-Caniupan, Adolfo Hernandez-Garduno, Monica Alva-Esqueda, Therese Aubry-de Maraumont, Luis M. Camacho-Cordero
Summary: In patients with multiple myeloma, denosumab is a cost-effective intervention compared to the Mix ZA/No trt.
GACETA MEXICANA DE ONCOLOGIA
(2022)